Market closed
enVVeno Medical/$NVNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About enVVeno Medical
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Ticker
$NVNO
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
37
Website
enVVeno Medical Metrics
BasicAdvanced
$40M
-
-$1.27
1.38
-
Price and volume
Market cap
$40M
Beta
1.38
52-week high
$6.48
52-week low
$2.10
Average daily volume
99K
Financial strength
Current ratio
20.875
Quick ratio
20.598
Long term debt to equity
1.66
Total debt to equity
2.524
Management effectiveness
Return on assets (TTM)
-31.82%
Return on equity (TTM)
-49.39%
Valuation
Price to book
0.94
Price to tangible book (TTM)
0.94
Price to free cash flow (TTM)
-2.306
Growth
Earnings per share change (TTM)
-33.42%
3-year earnings per share growth (CAGR)
-12.56%
What the Analysts think about enVVeno Medical
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for enVVeno Medical stock.
enVVeno Medical Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
enVVeno Medical Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
enVVeno Medical News
AllArticlesVideos
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
Accesswire·1 week ago
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
Accesswire·1 month ago
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for enVVeno Medical stock?
enVVeno Medical (NVNO) has a market cap of $40M as of April 08, 2025.
What is the P/E ratio for enVVeno Medical stock?
The price to earnings (P/E) ratio for enVVeno Medical (NVNO) stock is 0 as of April 08, 2025.
Does enVVeno Medical stock pay dividends?
No, enVVeno Medical (NVNO) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next enVVeno Medical dividend payment date?
enVVeno Medical (NVNO) stock does not pay dividends to its shareholders.
What is the beta indicator for enVVeno Medical?
enVVeno Medical (NVNO) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.